Parambir Singh Dulai, MBBS

Parambir Dulai practices at Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare.

Parambir Dulai's NPI, 1811214364, was assigned on April 23, 2010. Parambir Dulai holds Illinois license 036158764.

Parambir Dulai's primary practice is Northwestern Memorial Hospital, at 251 E Huron St, Chicago, IL 60611 in Cook County. The practice phone is (312) 926-2000.

Parambir Dulai's primary practice is Northwestern Memorial Hospital in Chicago, Illinois, part of Northwestern Memorial HealthCare. Parambir Dulai is also affiliated with Northwestern Medicine Central DuPage Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Parambir Dulai to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Parambir Dulai practices, 3 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Parambir Dulai's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Parambir Dulai's licenses on file in 2 states: Illinois and California.

CMS data shows 11 Medicare services from Parambir Dulai across 1 procedure code in 2024, for 43 Medicare patients. Medicare paid $1,929 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 43 Medicare patients who saw Parambir Dulai in 2024. The largest group is 65 to 74, with 29 patients. 72% of them have high cholesterol, and 58% have high blood pressure. Their average risk score is 1.51, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Parambir Dulai's median patient age at 44, with 51% women.

In 2024, Parambir Dulai wrote 89 Medicare Part D claims for 41 patients. 67% of them were for generic drugs. CMS names the drug for 31 of them, across 2 drugs with 11 or more claims each, at $2,135 in total drug cost. In 2023, CMS named 30 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Parambir Dulai for performance year 2024, reported through an alternative payment model (APM). Parambir Dulai accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Parambir Dulai as offering telehealth.

Colonoscopy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 229 papers to Parambir Dulai, published from 2011 to 2025. 2020 was the busiest year, with 38. The most frequent topics are Colitis, Ulcerative, Crohn Disease and Remission Induction. Parambir Dulai has published most often in Clin Gastroenterol Hepatol. Parambir Dulai's most frequent co-authors are William J. Sandborn, MD, Siddharth Singh, MBBS and Gursimran Singh Kochhar, MD.

Dmand AI links Parambir Dulai to 1 clinical trial. Conditions studied include Colitis, Ulcerative and Colitis.

CMS Open Payments shows 474 general payments to Parambir Dulai from 19 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 45% of the total. Takeda Pharmaceuticals U.S.A., Inc. paid the most, $282,662. It also lists 7 research payments totaling $2,169 from 2017 to 2025.